NCT07752420Active, not recruiting
Effects of Structural Integration on Chest Wall Expansion Among COPD Patients
Effects of "The 10-Series of Structural Integration" on Chest Wall Expansion Among COPD Patients
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The present study aims to investigate the effects of the 10-Series of Structural Integration on chest wall expansion in patients with stable COPD using a randomized controlled trial design. Participants receiving Structural Integration in addition to conventional pulmonary rehabilitation will be compared with those receiving conventional pulmonary rehabilitation alone. Chest wall expansion will serve as the primary outcome, while pulmonary function, dyspnea, functional exercise capacity, and quality of life may be evaluated as secondary outcomes.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 4 Aug 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 15 Nov 2026
- Lead sponsor
- Green International University
- Diseases
- COPD
- NCT number
- NCT07752420
What you commit to
- Study type: Interventional
- Planned participants: 52
- From 1 Sept 2026 to the primary completion date, 15 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent thoracic or abdominal surgery (\<6 months)
- Previous Structural Integration treatment within the last year
Other illness
- Severe cardiovascular disease contraindicating exercise
- Neurological disorders affecting mobility
- Active malignancy
Other
- Rib fractures or severe chest wall deformity
- Severe osteoporosis with high fracture risk
Who the study is looking for
- Clinically diagnosed stable COPD according to GOLD criteria
- GOLD stage II or III
- No acute exacerbation within the previous four weeks
- Able to ambulate independently
- Medically cleared to participate in pulmonary rehabilitation
- Willing to provide written informed consent
Age in the registry: 50 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ali Fatima Hospital Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.